The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis
Costa V, Ungar WJ, Hancock R
Record ID 32011000114
English
Authors' objectives:
The primary objective was to evaluate the clinical efficacy and safety evidence available for biologic drugs used in the treatment of the polyarticular subtype of JIA. The secondary objectives were to compare costs and cost-effectiveness of treatment with each biologic drug to conventional treatment, comprised of an optimized non-biologic DMARD regiment. This report focuses on patients with the polyarticular-course JIA subtype. Results of studies conducted exclusively in children with systemic JIA are reported separately (see report appendices).
Authors' recommendations:
The current evidence shows a short-term improvement in disease status following treatment with biologics in patients with polyarticular JIA who had previously had an inadequate response to conventional treatment. It is believed that better control of the disease may result in improvement in important long-term clinical outcomes, such as functional disability, which may affect social life, employment, and quality of life. Long-term treatment outcomes data, however, are not presently available. Disease registries may provide additional evidence on clinical benefits and safety issues in patients treated with these drugs.
Along with a potential for improvement in important long-term clinical outcomes in some patients comes a potential for a considerable health care payer budget impact given the number of patients that may need treatment and the length of treatment. Moreover, important long-term safety concerns have also been raised. All these factors need to be taken into account and should be further evaluated in allocation decisions.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
https://lab.research.sickkids.ca/task/wp-content/uploads/sites/66/2018/06/2010-01-Biologics-JIA-Full-Report.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal
Contact
Organisation Name:
Technology Assessment at SickKids
Contact Address:
Program of Child Health Evaluative Sciences, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8 tel: (416) 813-8519 fax: (416) 813-5979
Contact Name:
wendy.ungar@sickkids.ca
Contact Email:
wendy.ungar@sickkids.ca
Copyright:
<p>The Hospital for Sick Children Research Institute</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.